Cytosorbents Corporation（CTSO）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · CTSO · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$37.06M	$35.59M	$31.08M	$34.69M	$40.11M
Cost of Revenue	$10.57M	$10.71M	$9.13M	$13.96M	$11.05M
Gross Profit	$26.49M	$24.89M	$21.95M	$20.73M	$29.06M
Gross Margin %(computed)	71.48%	69.92%	70.62%	59.77%	72.46%
Operating Expenses
R&D Expenses	$5.08M	$7.61M	$15.59M	$15.12M	$16.38M
G&A Expenses	$0.00M	$0.00M	$37.87M	$2.21M	$38.48M
Total Operating Expenses	$40.73M	$41.34M	$53.90M	$52.25M	$51.81M
Operating Income	($14.24M)	($16.45M)	($31.95M)	($31.52M)	($22.74M)
Operating Margin %(computed)	-38.42%	-46.22%	-102.78%	-90.87%	-56.71%
Interest Income	$0.00M	$0.00M	$0.00M	$0.13M	$0.03M
Interest Expense	$2.61M	$1.40M	$0.16M	$0.00M	$0.00M
Income Before Tax	($8.60M)	($22.41M)	($30.06M)	($33.91M)	($25.29M)
Income Tax Expense	($0.40M)	($1.69M)	($0.81M)	($1.09M)	($0.74M)
Net Income	($8.20M)	($20.72M)	($29.25M)	($32.81M)	($24.56M)
Net Margin %(computed)	-22.12%	-58.21%	-94.09%	-94.59%	-61.23%
Per Share & EBITDA
EPS (Basic)	$-0.13	$-0.38	$-0.65	$-0.75	$-0.57
Wtd Avg Shares	62.23M	54.43M	44.66M	43.57M	43.36M
EBITDA	($4.36M)	($19.27M)	($27.88M)	($30.00M)	($21.62M)
EBITDA Margin %(computed)	-11.75%	-54.13%	-89.69%	-86.49%	-53.89%